%0 Journal Article
%T On the evolution of high-dose immunosuppressive therapy with autologous stem cell transplantation in multiple sclerosis
%A Athanasios Fassas
%J Cellular Therapy and Transplantation
%D 2010
%I 
%X High-dose immunosuppressive therapy with hemopoietic stem cell transplantation (HSCT) was already introduced into the management of multiple sclerosis (MS) in 1995. HSCT has been shown to be a most powerful immunosuppressive and anti-inflammatory treatment. Since 2000, all communications have consistently reported a dramatic, almost 100%, reduction in, or disappearance of, disease activity (inflammation) on magnetic resonance imaging (MRI), which is retained over time and has not been observed as an outcome of any other MS treatment. Despite the very interesting outcomes of HSCT in treatment of MS, it is only in comparative trials that its superiority over other therapies can be demonstrated. Therefore, it is absolutely necessary to complete the running randomized studies comparing HSCT with mitoxantrone (ASTIMS) or other standard therapies. Unless such trials yield their final results, HSCT will never be approved as an established therapy for MS patients who may so miss the opportunity of receiving an active, powerful immunosuppressive and immunomodulating treatment having a long-term beneficial impact on the course of the disease.
%K multiple sclerosis
%K hematopoietic stem cell transplantation
%K high-dose immunosuppressive therapy
%U http://www.ctt-journal.com/index.php?id=418